Submit Manuscript  

Article Details

Novel Long-acting Pharmacotherapy for Exudative Age Related Macular Degeneration


Elad Moisseiev* and Anat Loewenstein   Pages 1 - 4 ( 4 )


Exudative age-related macular degeneration (AMD) is a major indication for the administration of intravitreal injections of anti-VEGF agents, which have been established as a very effective pharmacotherapy for this disease. However, treatment with anti-VEGF agents requires several patient visits for monitoring and treatment. Strategies for achieving a longer duration of pharmacological action are currently being developed. These include the development of longer-acting drugs, and of novel technologies to increase the duration of action of administered agents. This manuscript will review the novel drugs and technologies currently being developed for achieving a longer-action pharmacotherapy for exudative AMD.


Age related macular degeneration, long term, long acting, intravitreal therapy.


Department of Ophthalmology, Meir Medical Center, Kfar Saba, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv

Read Full-Text article